Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 5, 2013, Pages 2879-2883

  Zhang, Yan ^a   Wang, Qiang ^a   Han, Zhi Gang ^a   Shan, Li ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Genetic mutation; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; COMPARATIVE STUDY; ETHNIC GROUP; EXON; FEMALE; GENE DELETION; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; POINT MUTATION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; ETHNIC GROUPS; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POINT MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION;

EID: 84880384586     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.5.2879     Document Type: Article

References (14)

1. Huang SF, Liu HP, Li LH (2004). High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancer related to gefitinib responsiveness in Taiwan. Clin Cancer Res, 10, 8195-203.
2. Inal A, Kaplan MA, Kucukoner M, et al (2012). Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution. Asian Pac J Cancer Prev, 13, 1281-4.
3. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
4. Lynch TJ, Bell DW, Sordella R (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.
5. Marchetti A, Martella C, Felicioni L (2005). EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol, 23, 857-65.
6. MILLER VA, O'CONNOR P, SOH C (2009). A randomized, double-blind, placeb controlled, phase IIIb trial (atlas) comparing bevacizumab(B) therapy with or without erlotinib(E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic nonsmall cell lung. J Clin Oncol, 27, abstrLBA8002.
7. Mu XL, Li LY, Zhang XT (2005). Gefitinib-sensitive mutations of the epidermal growth factor receptor thyosine domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res, 11, 4289-94.
8. Paez JG, Janner PA, Lee JC(2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500.
9. Pao W, Miller V, Zakowski M (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101, 13306-11.
10. Qin BM, Chen X, Zhu JD (2005). Identification of EGFR kinase domain mutaitions among lung cancer patients in China:implication for targeted cancer therapy. Cell Res, 15, 212-7.
11. Shigematsu H, Lin L, Takahashi T (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 97, 339-46.
12. Tokumo M, Toyooka S, Kiura K (2005). The relationship between epidermal gorwth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res, 11, 1167-73.
13. Xiao H, Ding J, Gao S, Yang S, Huang Y (2011). Never smokers with lung cancer: analysis of genetic variants. Asian Pac J Cancer Prev, 12, 2807-9.
14. Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol, 12, 735-42.